Renal Cell Carcinoma Clinical Trials 2023

Renal Cell Carcinoma Clinical Trials 2023

Renal Cell Carcinoma research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in renal cell carcinoma clinical trials today.

Renal Cell Carcinoma Clinical Trials

Here are the 6 most popular medical studies for renal cell carcinoma

Popular filter options for renal cell carcinoma trials

Kidney Cancer Clinical Trials

View 64 Kidney Cancer medical studies.

Kidney Cell Carcinoma Clinical Trials

View 64 Kidney Cell Carcinoma medical studies.

PD-L1 Positive Clinical Trials

View 21 PD-L1 positive medical studies.

PD-1 Positive Clinical Trials

View 21 PD-1 positive medical studies.

Phase 3 Renal Cell Carcinoma Clinical Trials

View 98 phase 3 renal cell carcinoma medical studies.

Renal Cell Carcinoma Clinical Trials With No Placebo

View 98 renal cell carcinoma medical studies that do not have a placebo group.

View More Renal Cell Carcinoma Trials

See another 72 many medical studies focused on renal cell carcinoma.

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to renal cell carcinoma

What are the top hospitals conducting renal cell carcinoma research?

When it comes to cutting-edge clinical trials for renal cell carcinoma, several leading hospitals are making significant strides in finding new treatments and improving outcomes. In Houston, MD Anderson Cancer Center takes the lead with eight active trials dedicated to this type of kidney cancer and an impressive 24 completed trials since their first recorded study in 2003. Meanwhile, Massachusetts General Hospital in Boston is also at the forefront of research, currently conducting seven ongoing renal cell carcinoma trials and boasting a rich history of 35 previous studies dating back to their initial trial in 2007.

In New York City, researchers at Memorial Sloan Kettering Cancer Center have made substantial contributions as well. With seven ongoing clinical trials focused on renal cell carcinoma and an impressive track record of 47 completed studies since their inaugural trial in 2003, they continue to push boundaries in understanding this complex disease. Further expanding the list is Cleveland Clinic located in Cleveland where researchers are actively engaged with seven renal cell carcinoma trials while successfully completing twenty investigations from initiating its first recorded study on this specific cancer type back until year2009; noteworthy mention goes out recognizing M D Anderson Cancer Center's efforts located within Houston as another hub engagingly participating by having parallel accomplishments offering similar number (seven)of current actively running clinical tests whilst holding experience being partaken throughout thirty-six experiments starting right from earliest known research conducted two decades ago specifically targeting Renal Cell Carcinoma when traced way back until year 2000.

These renowned medical institutions reflect not only a commitment to advancing treatment options for patients battling renal cell carcinoma but also shining examples of collaboration and innovation across different locations nationwide. The tireless efforts exerted by these top-tier hospitals serve as beacons of hope for individuals affected by this challenging condition while propelling us closer towards breakthroughs that can potentially transform lives around the world

Which are the best cities for renal cell carcinoma clinical trials?

When it comes to renal cell carcinoma clinical trials, several cities stand out for their significant research efforts. In Boston, Massachusetts, there are 45 active trials focusing on promising treatments such as Nivolumab, Belzutifan, and Pembrolizumab/Quavonlimab. New York City follows closely with 40 ongoing studies exploring the efficacy of Pembrolizumab, BMS-986340, and DFF332. Houston in Texas also plays a crucial role with 31 active trials investigating treatments like Nivolumab and Pembrolizumab. These cities offer individuals battling renal cell carcinoma access to cutting-edge clinical trials that could potentially revolutionize treatment options and improve patient outcomes.

Which are the top treatments for renal cell carcinoma being explored in clinical trials?

Renal cell carcinoma research is making significant strides in uncovering new and effective treatments. Leading the way are several promising options being explored in clinical trials:

  • Pembrolizumab: This breakthrough drug is currently undergoing testing in seven active trials for renal cell carcinoma. Since its introduction in 2013, it has been a key player in 60 all-time trials dedicated to fighting this type of cancer0 all-time trials dedicated to fighting this type of cancer.

  • Belzutifan: With six ongoing clinical trials and 14 all-time renal cell carcinoma studies, belzutifan shows promise as an emerging treatment option. It was first listed as a potential therapy in 2016.

  • Nivolumab: Another formidable contender on the scene is nivolumab, with five active clinical trials and an impressive track record of participating in 91 all-time renal cell carcinoma studies since its initial listing back in 2012.

These innovative therapies bring hope to patients battling renal cell carcinoma and represent significant progress towards improved outcomes for affected individuals worldwide.

What are the most recent clinical trials for renal cell carcinoma?

Recent clinical trials for renal cell carcinoma offer new hope and potential treatment options for patients. One such trial, Arm 2, explores the combination of nivolumab, ipilimumab, and camu camu in a Phase 1 study. Additionally, ARM I focuses on standard care SBRT in a Phase 2 trial. Another promising study is Cohort 1's investigation into cabozantinib dose escalation during a Phase 2 trial. Furthermore, the Expansion Triplet combination holds promise as it undergoes evaluation in a Phase 2 study. Lastly, NPX267 is being tested in a Phase 1 trial to assess its efficacy against renal cell carcinoma. These recent clinical trials provide encouraging developments that may lead to improved outcomes for patients battling this challenging condition.

What renal cell carcinoma clinical trials were recently completed?

Several clinical trials investigating treatments for renal cell carcinoma have recently been completed, reflecting the ongoing efforts to advance therapeutic options for this form of kidney cancer. Notably, a trial sponsored by UNC Lineberger Comprehensive Cancer Center concluded in October 2020 and focused on evaluating Perflutren lipid microsphere as a potential treatment. In August 2020, two trials came to an end: one led by Arrowhead Pharmaceuticals exploring ARO-HIF2 therapy and another conducted by Celldex Therapeutics investigating CDX-527. These studies highlight the dedication of researchers and bring hope for future advancements against renal cell carcinoma.